High hydrophobic amino acid exposure is responsible of the neurotoxic effects induced by E200K or D202N disease-related mutations of the human prion protein-Reference-Cited by-同舟云学术

High hydrophobic amino acid exposure is responsible of the neurotoxic effects induced by E200K or D202N disease-related mutations of the human prion protein

Published:2011-03 Issue:3 Volume:43 Page:372-382
ISSN:1357-2725
Container-title:The International Journal of Biochemistry & Cell Biology
language:en
Short-container-title:The International Journal of Biochemistry & Cell Biology

Author:

Corsaro Alessandro,Thellung Stefano,Bucciarelli Tonino,Scotti Luca,Chiovitti Katia,Villa Valentina,D’Arrigo Cristina,Aceto Antonio,Florio Tullio

Funder

Italian Ministry of University and Research

Compagnia di San Paolo

Publisher

Elsevier BV

Subject

Cell Biology,Biochemistry

Reference56 articles.

1. The intriguing prion disorders;Abid;Cell Mol Life Sci,2006

2. Structural and functional properties of the 34-kDa fragment produced by the N-terminal chymotryptic cleavage of glutathione transferase P1-1;Aceto;Arch Biochem Biophys,1995

3. Prion diseases of humans and farm animals: epidemiology, genetics, and pathogenesis;Aguzzi;J Neurochem,2006

4. Mammalian prion biology: one century of evolving concepts;Aguzzi;Cell,2004

5. Pathway complexity of prion protein assembly into amyloid;Baskakov;J Biol Chem,2002

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Copper homeostasis and cuproptosis in mitochondria;Life Sciences;2023-12

2. Y225A induces long-range conformational changes in human prion protein that are protective in Drosophila;Journal of Biological Chemistry;2023-07

3. Insights into the promising prospect of medicinal chemistry studies against neurodegenerative disorders;Chemico-Biological Interactions;2023-03

4. Proteostasis unbalance in prion diseases: Mechanisms of neurodegeneration and therapeutic targets;Frontiers in Neuroscience;2022-09-06

5. Medicinal Chemistry Studies Against Neurodegenerative Diseases;Current Neuropharmacology;2022-05